Please login to the form below

gantenerumab

This page shows the latest gantenerumab news and features for those working in and with pharma, biotech and healthcare.

Roche also had updated results from a previously-reported trial of its gantenerumab candidate that failed to show a benefit on cognition.

Biogen Idec claims first with Alzheimer's candidate

That view took a knock last December however when Roche announced it was halting a phase III trial of its gantenerumab candidate in prodromal Alzheimer's after an independent panel concluded
AB Science on track for phase III data in Alzheimer's this year

of patients, with a host of failed projects including most recently Roche's gantenerumab.
Double trial disappointment for Roche

The Swiss pharma company will discontinue a phase III programme investigating its anti-amyloid medicine gantenerumab in people in the early stages of Alzheimer's after an analysis of interim data. ... Roche has not given up on gantenerumab completely,
Novartis launches Alzheimer’s prevention study

One of the drugs to fail at this late stage – Lilly's solanezumab – is currently being tested in an Alzheimer's prevention study alongside Roche's dementia hope gantenerumab. ... Like many other investigational Alzheimer's treatments solanezumab and
Eisai and Biogen partner on Alzheimer’s

Other Alzheimer's antibodies include Roche's gantenerumab and Lilly's solanezumab.

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Alzheimer’s disease: reviewing the immediate treatment horizon

Crenezumab, gantenerumab, and solanezumab are all involved in additional prospective longitudinal investigations – the Alzheimer’ s Prevention Initiative (Phase 2), the Dominantly Inherited Alzheimer Network study (Phase 2/3), and the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...